pasted image 150x61.jpg

ADMA Biologics (NASDAQ: ADMA) is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. ADMA's product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.

ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of its lead product candidate RI-002.

On October 22, 2013 ADMA Biologics announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share.